ORCHESTRA BIOMED HOLDINGS INC. - ORDINARY SHARES

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

19 9 2023 06:30:00 提供 Nasdaq GlobeNewswire

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

10 8 2023 15:34:21 提供 Nasdaq GlobeNewswire

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

08 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

26 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

07 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Orchestra BioMed to Present at the Jefferies Global Healthcare Conference

01 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

12 5 2023 08:15:18 提供 Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

07 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

24 2 2023 07:00:00 提供 Nasdaq GlobeNewswire